Which has preferable earnings & valuation, QURE or IMVT?

uniQure has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio uniQure $16.10M 97.03 -$198.97M -$4.01 N/A Immunovant N/A N/A -$505.61M -$2.82 N/A

Is QURE or IMVT more profitable?

Immunovant has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. Immunovant's return on equity of -69.59% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets uniQure -1,350.73% -111.96% -29.01% Immunovant N/A -69.59% -62.49%

Does the media prefer QURE or IMVT?

In the previous week, Immunovant had 9 more articles in the media than uniQure. MarketBeat recorded 12 mentions for Immunovant and 3 mentions for uniQure. Immunovant's average media sentiment score of 0.29 beat uniQure's score of 0.25 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Immunovant 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor QURE or KNSA?

In the previous week, uniQure and uniQure both had 3 articles in the media. Kiniksa Pharmaceuticals International's average media sentiment score of 0.91 beat uniQure's score of 0.25 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Kiniksa Pharmaceuticals International 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor QURE or RYTM?

In the previous week, Rhythm Pharmaceuticals had 14 more articles in the media than uniQure. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 3 mentions for uniQure. uniQure's average media sentiment score of 0.25 beat Rhythm Pharmaceuticals' score of 0.24 indicating that uniQure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IOVA or QURE?

In the previous week, Iovance Biotherapeutics had 6 more articles in the media than uniQure. MarketBeat recorded 9 mentions for Iovance Biotherapeutics and 3 mentions for uniQure. Iovance Biotherapeutics' average media sentiment score of 0.79 beat uniQure's score of 0.25 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is QURE or KOD more profitable?

Kodiak Sciences has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. uniQure's return on equity of -111.96% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets uniQure -1,350.73% -111.96% -29.01% Kodiak Sciences N/A -273.23% -85.48%

Does the media favor QURE or KOD?

In the previous week, Kodiak Sciences had 11 more articles in the media than uniQure. MarketBeat recorded 14 mentions for Kodiak Sciences and 3 mentions for uniQure. Kodiak Sciences' average media sentiment score of 0.67 beat uniQure's score of 0.25 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Kodiak Sciences 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

uniQure (QURE) Competitors

$21.96 -0.56 (-2.48%)

As of 11:20 AM Eastern

Compare

QURE vs. IMVT, KNSA, RYTM, IOVA, and KOD

Should you buy uniQure stock or one of its competitors? uniQure's main competitors and comparable companies include Immunovant (IMVT), Kiniksa Pharmaceuticals International (KNSA), Rhythm Pharmaceuticals (RYTM), Iovance Biotherapeutics (IOVA), and Kodiak Sciences (KOD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does uniQure compare to Immunovant?

uniQure (NASDAQ:QURE) and Immunovant (NASDAQ:IMVT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

uniQure currently has a consensus price target of $53.25, suggesting a potential upside of 136.46%. Immunovant has a consensus price target of $44.00, suggesting a potential upside of 59.94%. Given uniQure's stronger consensus rating and higher possible upside, equities analysts clearly believe uniQure is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

uniQure has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	97.03	-$198.97M	-$4.01	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

Immunovant has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. Immunovant's return on equity of -69.59% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Immunovant	N/A	-69.59%	-62.49%

uniQure has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

78.8% of uniQure shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 4.7% of uniQure shares are held by insiders. Comparatively, 1.9% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Immunovant had 9 more articles in the media than uniQure. MarketBeat recorded 12 mentions for Immunovant and 3 mentions for uniQure. Immunovant's average media sentiment score of 0.29 beat uniQure's score of 0.25 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Immunovant	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

uniQure beats Immunovant on 10 of the 15 factors compared between the two stocks.

How does uniQure compare to Kiniksa Pharmaceuticals International?

uniQure (NASDAQ:QURE) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

78.8% of uniQure shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 4.7% of uniQure shares are owned by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kiniksa Pharmaceuticals International has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	97.03	-$198.97M	-$4.01	N/A
Kiniksa Pharmaceuticals International	$677.56M	9.20	$59.01M	$0.97	82.41

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to uniQure's net margin of -1,350.73%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

uniQure has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market.

uniQure currently has a consensus target price of $53.25, indicating a potential upside of 136.46%. Kiniksa Pharmaceuticals International has a consensus target price of $93.14, indicating a potential upside of 16.52%. Given uniQure's higher probable upside, research analysts plainly believe uniQure is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

In the previous week, uniQure and uniQure both had 3 articles in the media. Kiniksa Pharmaceuticals International's average media sentiment score of 0.91 beat uniQure's score of 0.25 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kiniksa Pharmaceuticals International beats uniQure on 9 of the 15 factors compared between the two stocks.

How does uniQure compare to Rhythm Pharmaceuticals?

uniQure (NASDAQ:QURE) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

Rhythm Pharmaceuticals has a net margin of -85.59% compared to uniQure's net margin of -1,350.73%. uniQure's return on equity of -111.96% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

In the previous week, Rhythm Pharmaceuticals had 14 more articles in the media than uniQure. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 3 mentions for uniQure. uniQure's average media sentiment score of 0.25 beat Rhythm Pharmaceuticals' score of 0.24 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Rhythm Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

uniQure has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 2.01, meaning that its share price is 101% more volatile than the broader market.

Rhythm Pharmaceuticals has higher revenue and earnings than uniQure. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	97.03	-$198.97M	-$4.01	N/A
Rhythm Pharmaceuticals	$189.76M	31.77	-$196.54M	-$3.11	N/A

78.8% of uniQure shares are owned by institutional investors. 4.7% of uniQure shares are owned by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

uniQure presently has a consensus price target of $53.25, indicating a potential upside of 136.46%. Rhythm Pharmaceuticals has a consensus price target of $142.50, indicating a potential upside of 61.99%. Given uniQure's stronger consensus rating and higher possible upside, analysts clearly believe uniQure is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76

Summary

uniQure and Rhythm Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does uniQure compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Iovance Biotherapeutics presently has a consensus target price of $13.20, indicating a potential downside of 10.33%. uniQure has a consensus target price of $53.25, indicating a potential upside of 136.46%. Given uniQure's stronger consensus rating and higher probable upside, analysts clearly believe uniQure is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
uniQure	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 4.7% of uniQure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Iovance Biotherapeutics had 6 more articles in the media than uniQure. MarketBeat recorded 9 mentions for Iovance Biotherapeutics and 3 mentions for uniQure. Iovance Biotherapeutics' average media sentiment score of 0.79 beat uniQure's score of 0.25 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Iovance Biotherapeutics has a net margin of -89.11% compared to uniQure's net margin of -1,350.73%. Iovance Biotherapeutics' return on equity of -40.51% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
uniQure	-1,350.73%	-111.96%	-29.01%

uniQure has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	25.30	-$390.98M	-$0.73	N/A
uniQure	$16.10M	97.03	-$198.97M	-$4.01	N/A

Iovance Biotherapeutics has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, uniQure has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Summary

uniQure beats Iovance Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does uniQure compare to Kodiak Sciences?

uniQure (NASDAQ:QURE) and Kodiak Sciences (NASDAQ:KOD) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Kodiak Sciences has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. uniQure's return on equity of -111.96% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Kodiak Sciences	N/A	-273.23%	-85.48%

uniQure has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	97.03	-$198.97M	-$4.01	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A

uniQure has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.03, indicating that its share price is 103% more volatile than the broader market.

uniQure presently has a consensus price target of $53.25, suggesting a potential upside of 136.46%. Kodiak Sciences has a consensus price target of $104.71, suggesting a potential upside of 18.83%. Given uniQure's stronger consensus rating and higher possible upside, analysts clearly believe uniQure is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Kodiak Sciences had 11 more articles in the media than uniQure. MarketBeat recorded 14 mentions for Kodiak Sciences and 3 mentions for uniQure. Kodiak Sciences' average media sentiment score of 0.67 beat uniQure's score of 0.25 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Kodiak Sciences	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

78.8% of uniQure shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 4.7% of uniQure shares are owned by insiders. Comparatively, 44.4% of Kodiak Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

uniQure beats Kodiak Sciences on 9 of the 15 factors compared between the two stocks.

Get uniQure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QURE vs. The Competition

Export

Metric	uniQure	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.54B	$3.93B	$7.43B	$12.86B
Dividend Yield	N/A	3.66%	2.51%	19.61%
P/E Ratio	-5.53	12.63	274.94	25.22
Price / Sales	82.31	1,201.64	623.57	99.68
Price / Cash	N/A	118.95	76.19	51.56
Price / Book	6.95	16.07	10.40	5.96
Net Income	-$198.97M	-$22.69M	$3.50B	$380.92M
7 Day Performance	-1.92%	-6.92%	-3.89%	-3.33%
1 Month Performance	-47.86%	-12.35%	-7.10%	-5.34%
1 Year Performance	-63.07%	2.13%	1.70%	-4.58%

uniQure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QURE uniQure	3.6843 of 5 stars	$21.96 -2.5%	$53.25 +142.5%	-64.2%	$1.53B	$18.67M	N/A	221	Analyst Forecast
IMVT Immunovant	2.4254 of 5 stars	$30.47 +0.7%	$44.00 +44.4%	+53.4%	$6.25B	N/A	N/A	315
KNSA Kiniksa Pharmaceuticals International	4.0562 of 5 stars	$79.78 +1.3%	$93.14 +16.7%	+105.7%	$6.14B	$677.56M	82.25	366	News Coverage
RYTM Rhythm Pharmaceuticals	2.4508 of 5 stars	$90.78 +1.3%	$140.89 +55.2%	-19.6%	$6.14B	$189.76M	N/A	414	Analyst Forecast Analyst Revision
IOVA Iovance Biotherapeutics	2.1148 of 5 stars	$14.62 +9.8%	$12.90 -11.8%	+557.1%	$6.03B	$263.50M	N/A	975	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QURE) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

uniQure (QURE) Competitors

QURE vs. IMVT, KNSA, RYTM, IOVA, and KOD

How does uniQure compare to Immunovant?

Summary

How does uniQure compare to Kiniksa Pharmaceuticals International?

Summary

How does uniQure compare to Rhythm Pharmaceuticals?

Summary

How does uniQure compare to Iovance Biotherapeutics?

Summary

How does uniQure compare to Kodiak Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

uniQure (QURE) Competitors

QURE vs. IMVT, KNSA, RYTM, IOVA, and KOD

How does uniQure compare to Immunovant?

Do analysts rate QURE or IMVT?

Which has preferable earnings & valuation, QURE or IMVT?

Is QURE or IMVT more profitable?

Which has more risk and volatility, QURE or IMVT?

Do insiders & institutionals hold more shares of QURE or IMVT?

Does the media prefer QURE or IMVT?

Summary

How does uniQure compare to Kiniksa Pharmaceuticals International?

Do insiders and institutionals hold more shares of QURE or KNSA?

Which has better valuation and earnings, QURE or KNSA?

Is QURE or KNSA more profitable?

Which has more volatility & risk, QURE or KNSA?

Do analysts prefer QURE or KNSA?

Does the media favor QURE or KNSA?

Summary

How does uniQure compare to Rhythm Pharmaceuticals?

Is QURE or RYTM more profitable?

Does the media favor QURE or RYTM?

Which has more volatility and risk, QURE or RYTM?

Which has higher earnings & valuation, QURE or RYTM?

Do institutionals & insiders hold more shares of QURE or RYTM?

Do analysts prefer QURE or RYTM?

Summary

How does uniQure compare to Iovance Biotherapeutics?

Do analysts prefer IOVA or QURE?

Do institutionals and insiders believe in IOVA or QURE?

Does the media prefer IOVA or QURE?

Is IOVA or QURE more profitable?

Which has better earnings and valuation, IOVA or QURE?

Which has more risk & volatility, IOVA or QURE?

Summary

How does uniQure compare to Kodiak Sciences?

Is QURE or KOD more profitable?

Which has preferable earnings and valuation, QURE or KOD?

Which has more volatility and risk, QURE or KOD?

Do analysts recommend QURE or KOD?

Does the media favor QURE or KOD?

Do insiders and institutionals have more ownership in QURE or KOD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools